Central Sleep Apnea Beyond Heart Failure

Primary Etiologies of Central Sleep Apnea

• Neurological disorders, such as stroke, can disrupt respiratory control centers, leading to central sleep apnea, according to the American Academy of Sleep Medicine 1
• Atrial fibrillation can cause central sleep apnea with a shorter cycle length (<45 seconds) compared to the longer cycle length (45-75 seconds) typically seen in heart failure, as noted by the American Academy of Sleep Medicine 1
• Pulmonary hypertension is associated with central sleep apnea independent of heart failure, as reported by the American Academy of Sleep Medicine 1
• Renal failure can lead to central sleep apnea through metabolic derangements affecting respiratory drive, according to the American Academy of Sleep Medicine 1
• Treatment-emergent central sleep apnea occurs in approximately 1% of patients starting CPAP therapy for obstructive sleep apnea, typically resolving within 1-3 months, as stated by the American Academy of Sleep Medicine 1

Pathophysiological Mechanisms

• Chemical control instability is a primary mechanism underlying most cases of central sleep apnea, which occur during light sleep (stages N1 and N2) when breathing is primarily under chemical control (CO₂-dependent), as explained by the American Academy of Sleep Medicine 2

Clinical Presentation Differences by Etiology

• Heart failure-associated central sleep apnea typically presents with Cheyne-Stokes respiration pattern and a long cycle length (45-75 seconds), often accompanied by orthopnea and paroxysmal nocturnal dyspnea, as described by the American Academy of Sleep Medicine 1, 3
• Medication-induced central sleep apnea may have a more abrupt onset, temporally related to medication initiation or dose increase, as noted by the American Academy of Sleep Medicine 4

Diagnostic Considerations

• Polysomnography is essential for diagnosis, showing central apneas without respiratory effort, as recommended by the American Geriatrics Society 5
• Cycle length assessment can help distinguish between heart failure-associated central sleep apnea (long cycle length, 45-75 seconds) and other forms of central sleep apnea (short cycle length, <45 seconds), which may be associated with atrial fibrillation, narcotics, pulmonary hypertension, renal failure, high altitude, and stroke, as reported by the American Academy of Sleep Medicine 1

Management Implications by Etiology

• Treatment of the underlying condition is the primary approach for most forms of central sleep apnea, as stated by Praxis Medical Insights 6
• Avoid suppressing compensatory central sleep apnea in heart failure, as it may be a compensatory mechanism that should not be suppressed after optimal medical therapy, as cautioned by Praxis Medical Insights 6

Central Sleep Apnea Diagnosis and Assessment

Initial Assessment and Diagnostic Testing

• The American Geriatrics Society recommends obtaining a detailed sleep history and inquiring about alcohol use and medication list, particularly focusing on sedative-hypnotics and opiate analgesics, which can contribute to central sleep apnea (CSA) 7
• Heart failure is the most common cause of CSA, according to the European Heart Journal 8
• The American Academy of Sleep Medicine recommends that polysomnography (PSG) should include measurement of oxygen saturation, rib cage and abdominal movement, nasal and oral airflow, sleep staging via electroencephalography, electrooculography, and electromyography, and electrocardiogram 7

Diagnostic Criteria and Severity Assessment

• CSA is diagnosed when the apnea-hypopnea index (AHI) is ≥5 events/hour with central events predominating, as defined by the American Academy of Sleep Medicine 9, 10
• The American Academy of Sleep Medicine recommends distinguishing between different types of sleep apnea, including obstructive sleep apnea (OSA), central sleep apnea (CSA), and complex sleep apnea, and notes that OSA is characterized by continued respiratory effort during apneas 9

Special Considerations

• Patients with heart failure may require referral to sleep specialists for proper management, as recommended by the American Geriatrics Society 7
• The American Academy of Sleep Medicine advises against relying solely on clinical tools, questionnaires, or prediction algorithms to diagnose CSA without polysomnography 9

Central Sleep Apnea Diagnosis and Treatment

Distinguishing Central from Obstructive Sleep Apnea

• The American Geriatrics Society and the American Academy of Sleep Medicine note that OSA is characterized by continued respiratory effort during apneas, while CSA shows absence of respiratory effort during apneic events 11, 12

Clinical Approach to Sleep Complaints

• The American Geriatrics Society recommends polysomnography to distinguish between OSA and CSA, and to look for OSA risk factors such as obesity and anatomic upper airway abnormalities 11

Treatment Implications

• The American Academy of Sleep Medicine states that CSA treatment depends on the underlying etiology, and that adaptive servo-ventilation (ASV) is contraindicated in heart failure patients with reduced ejection fraction and CSA due to increased mortality risk 13, 14

Common Pitfalls to Avoid

• The American Geriatrics Society and the American Academy of Sleep Medicine advise against assuming all apneas are the same type, and recommend polysomnography with assessment of respiratory effort to distinguish OSA from CSA 11, 12

Central Sleep Apnea Diagnosis and Differentiation

Diagnostic Criteria and Parameters

• The American Academy of Sleep Medicine recommends that polysomnography (PSG) must include oxygen saturation measurement, electrocardiogram, and nasal and oral airflow measurement to diagnose central sleep apnea (CSA) 15
• The diagnosis of CSA is made when the apnea-hypopnea index (AHI) is ≥5 events/hour with central events predominating, with severity classification following standard AHI thresholds: mild (5-14), moderate (15-29), severe (≥30) 15, 16

Polysomnographic Differentiation from Obstructive Sleep Apnea

• The American Academy of Sleep Medicine states that the key difference between central and obstructive sleep apnea is the presence or absence of respiratory effort during apneic events, with OSA showing continued respiratory effort and CSA demonstrating absent or diminished respiratory effort 17
• The polysomnographic features that differentiate OSA from CSA include the presence of respiratory effort, rib cage and abdominal movement, and upper airway obstruction in OSA, and the absence of these features in CSA 17

Clinical Presentation and Risk Factors

• Patients with central sleep apnea often have a higher prevalence of cardiovascular comorbidities, such as heart failure and arrhythmias, and may present with orthopnea and paroxysmal nocturnal dyspnea 16
• Independent risk factors for CSA include older age, comorbid arrhythmia or heart failure, elevated oxygen desaturation index, and lower body mass index 16

Treatment Implications

• The American Academy of Sleep Medicine recommends that treatment of underlying conditions is primary for CSA, and adaptive servo-ventilation (ASV) may be used for normocapnic CSA with ventilatory instability, but ASV is contraindicated in heart failure patients with reduced ejection fraction due to increased mortality risk 16, 17

Central Apnea–Induced Perioral Cyanosis: Evidence‑Based Findings

Mechanistic Features

• The American Academy of Sleep Medicine reports that central apneas frequently present as prolonged expiratory events with an initially open airway; the continued expiratory effort against a closed upper airway leads to progressive oxygen desaturation and visible perioral cyanosis【18】.

• In patients with heart failure, Cheyne‑Stokes respiration—a pattern of cyclic hyperventilation followed by central apneas—can produce severe hypoxemia during the apneic phase, resulting in cyanotic episodes despite partial compensation during the hyperventilatory phase【18】.

Pediatric and High‑Risk Populations

• In infants and children who have chronic lung disease, central apnea manifests with episodes of apnea, bradycardia, and either cyanosis or pallor; these cyanotic events can be life‑threatening, especially in the youngest patients【19】.

• Neurological disorders (e.g., stroke) that disrupt brainstem respiratory control are identified as a major risk factor for cyanotic central apneas, with a notable proportion of affected infants presenting with concurrent neurological impairment【19】 (note: the citation refers to the same source as the pediatric data).

Diagnostic Confirmation

• Polysomnography, as defined by the American Academy of Sleep Medicine, demonstrates central apneas characterized by the absence of thoraco‑abdominal respiratory effort on effort belts, confirming the lack of ventilatory drive during the event【20】.

• The same polysomnographic recordings show that oxygen desaturation occurs temporally with the central apneic episodes and that airflow traces lack the flattening pattern typical of obstructive events, thereby distinguishing central from obstructive apnea【20】.

Distinguishing Central from Obstructive Apnea

• Central apneas are defined by absent or markedly reduced respiratory effort during the apneic phase, whereas obstructive apneas display continued or increased effort against an occluded airway; this physiologic distinction is emphasized by the American Academy of Sleep Medicine guidelines【20】.

Prader‑Willi Syndrome and Central Sleep Apnea

Genetic and Developmental Disorders

• In infants with Prader‑Willi syndrome, central sleep apnea is detected in roughly 43 %, whereas the prevalence drops to about 5 % in older children (ages 2–18 years). American Academy of Sleep Medicine recommendation. 21

• Impaired ventilatory control and a high rate of scoliosis (15–86 % of individuals with Prader‑Willi syndrome) are identified as key contributors to the elevated risk of central sleep apnea in this population. American Academy of Sleep Medicine observation. 21

• American Academy of Sleep Medicine advises that polysomnography be performed at the time of Prader‑Willi syndrome diagnosis to screen for central apnea, with repeat testing approximately every six months for patients who have central adrenal insufficiency. 21